Eiger Biopharmaceuticals (NASDAQ:EIGR) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Tuesday. The firm presently has a $15.00 price target on the biotechnology company’s stock. Zacks Investment Research‘s target price points to a potential downside of 0.99% from the stock’s previous close.
According to Zacks, “Eiger BioPharmaceuticals, Inc. is a biopharmaceutical company which develops and manufactures drugs and therapies for the treatment of orphan diseases. Eiger BioPharmaceuticals, Inc., formerly known as Celladon Corporation, is based in Palo Alto, California. “
EIGR has been the subject of several other reports. Wedbush reaffirmed a “buy” rating on shares of Eiger Biopharmaceuticals in a report on Wednesday, October 25th. Oppenheimer set a $34.00 price target on Eiger Biopharmaceuticals and gave the stock a “buy” rating in a report on Monday, October 23rd. Roth Capital began coverage on Eiger Biopharmaceuticals in a report on Thursday, October 19th. They issued a “buy” rating and a $35.00 price target for the company. ValuEngine raised Eiger Biopharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, December 21st. Finally, Ladenburg Thalmann Financial Services began coverage on Eiger Biopharmaceuticals in a report on Wednesday, January 3rd. They issued a “buy” rating and a $32.00 price target for the company. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. Eiger Biopharmaceuticals has an average rating of “Buy” and an average target price of $30.63.
Shares of Eiger Biopharmaceuticals (EIGR) traded up $0.45 during mid-day trading on Tuesday, reaching $15.15. The company had a trading volume of 43,080 shares, compared to its average volume of 165,743. The firm has a market capitalization of $156.17, a PE ratio of -2.86 and a beta of 2.54. Eiger Biopharmaceuticals has a 52-week low of $6.10 and a 52-week high of $15.00. The company has a debt-to-equity ratio of 1.19, a quick ratio of 5.78 and a current ratio of 5.78.
Eiger Biopharmaceuticals (NASDAQ:EIGR) last issued its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($1.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.28) by $0.18. sell-side analysts anticipate that Eiger Biopharmaceuticals will post -4.59 EPS for the current year.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Susquehanna International Group LLP acquired a new position in shares of Eiger Biopharmaceuticals in the second quarter worth $114,000. Wedbush Securities Inc. acquired a new position in shares of Eiger Biopharmaceuticals in the third quarter worth $114,000. Bank of New York Mellon Corp raised its holdings in shares of Eiger Biopharmaceuticals by 6.4% in the second quarter. Bank of New York Mellon Corp now owns 14,567 shares of the biotechnology company’s stock worth $115,000 after acquiring an additional 871 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in shares of Eiger Biopharmaceuticals by 295.8% in the third quarter. JPMorgan Chase & Co. now owns 11,705 shares of the biotechnology company’s stock worth $126,000 after acquiring an additional 8,748 shares during the last quarter. Finally, OxFORD Asset Management LLP acquired a new position in shares of Eiger Biopharmaceuticals in the third quarter worth $147,000. 47.06% of the stock is owned by institutional investors.
WARNING: “Eiger Biopharmaceuticals (EIGR) Stock Rating Upgraded by Zacks Investment Research” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece on another site, it was copied illegally and republished in violation of US & international copyright & trademark law. The correct version of this piece can be accessed at https://www.dispatchtribunal.com/2018/01/11/eiger-biopharmaceuticals-eigr-stock-rating-upgraded-by-zacks-investment-research.html.
About Eiger Biopharmaceuticals
Eiger BioPharmaceuticals, Inc, formerly Celladon Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of orphan diseases. Its pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV), exendin (9-39) for severe hypoglycemia, and Bestatin (ubenimex) for pulmonary arterial hypertension (PAH) and lymphedema.
Receive News & Ratings for Eiger Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.